Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010
High Frequencies of Functional Tumor-Reactive T Cells in Bone Marrow and Blood of Pancreatic Cancer Patients
2005
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine
2007
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese
2012
EGFR Antagonists in Cancer Treatment
2008 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Inflammation and Cancer: Triggers, Mechanisms, and Consequences
2019 Standout
Reversible Cell‐Specific Drug Delivery with Aptamer‐Functionalized Liposomes
2009
Ovarian cancer
2014 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Inflammatory Myofibroblastic Tumor
2007 Standout
Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
2009
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Cytochrome P450IID6‐specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2†
2007
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Inflammatory myofibroblastic tumours: where are we now?
2007 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Hepatocellular carcinoma in HIV-infected patients
2004
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Colorectal cancer
2013 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
2006
Immunology and immunotherapy of colorectal cancer
2003
The LILR family: modulators of innate and adaptive immune pathways in health and disease
2004
Management of Hepatocellular Carcinoma *
2005 Standout
CD1d is expressed on B‐chronic lymphocytic leukemia cells and mediates α‐galactosylceramide presentation to natural killer T lymphocytes
2004
Aptamers as therapeutics
2010 Standout
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
Smooth muscle-like tissues engineered with bone marrow stromal cells
2003
Nasopharyngeal carcinoma
2015 Standout
Principles of adoptive T cell cancer therapy
2007
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
2007
Identification of CARS-ALK Fusion in Primary and Metastatic Lesions of an Inflammatory Myofibroblastic Tumor
2003
Control of Stem Cell Fate by Physical Interactions with the Extracellular Matrix
2009 Standout
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial
2012
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Successful Treatment of Inflammatory Myofibroblastic Tumor With Malignant Transformation by Surgical Resection and Chemotherapy
2003
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Cancer immunotherapy comes of age
2011 StandoutNature
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Neuroblastoma
2007 Standout
The Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer
2010
A Laser-Activated Biocompatible Theranostic Nanoagent for Targeted Multimodal Imaging and Photothermal Therapy
2017
Novel human polyomaviruses—Re‐emergence of a well known virus family as possible human carcinogens
2008 StandoutNobel
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
2008
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
Ovarian Tumorigenesis
2004
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Non-Classical HLA-G Antigen and Its Role in the Cancer Progression
2006
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Poly(lactide-co-glycolide)/hydroxyapatite composite scaffolds for bone tissue engineering
2005 Standout
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients
2013
Molecular pathogenesis of mantle cell lymphoma
2012
Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages
2017
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer
2008
Muc1 Immunotherapy
2010
INDUCTION OF UNDIFFERENTIATED TUMORS BY JC VIRUS IN THE CEREBRUM OF RATS
1986
The development of anticancer ruthenium(ii ) complexes: from single molecule compounds to nanomaterials
2017 Standout
Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release
2007
Multiple Myeloma
2010
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
2017 Standout
Small‐diameter human vessel wall engineered from bone marrow‐derived mesenchymal stem cells (hMSCs)
2008
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
2008
Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells
2006
Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
2001
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+T cells
2004
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Valvular endothelial cells and the mechanoregulation of valvular pathology
2007
Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency
2010 StandoutNobel
Multiple Myeloma
2011 Standout
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand
2012 StandoutNobel
A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer
2017
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives
2011 Standout
Inhibition of Mammary Carcinoma Development in HER-2/neu Transgenic Mice through Induction of Autoimmunity by Xenogeneic DNA Vaccination
2005
Works of Andreas Trojan being referenced
Leberveränderungen bei AIDS
1998
Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer
2004
Human Leukocyte Antigen G Up-Regulation in Lung Cancer Associates with High-Grade Histology, Human Leukocyte Antigen Class I Loss and Interleukin-10 Production
2001
Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma
2000
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials
2007
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
2000
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
2012
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
2008
HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy
2016
Inflammatory Myofibroblastic Tumor with CNS Involvement
2001
Induction of cytotoxic T-cell responses against immunoglobulin V region–derived peptides modified at human leukocyte antigen–A2 binding residues
2001
Progressive multifocal leukoencephalopathy--a case report and review of the literature.
2015
Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.
2001
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma
2004
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
2016
Tissue Engineering of Functional Trileaflet Heart Valves From Human Marrow Stromal Cells
2002
HLA‐G and its KIR ligands in cancer – another enigma yet to be solved?
2002